Lulizumab pegol: Difference between revisions
CSV import Tag: Reverted |
No edit summary Tag: Manual revert |
||
| Line 25: | Line 25: | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 12:59, 18 March 2025
Lulizumab pegol (also known as BMS-931699 or MDX-1106) is a monoclonal antibody designed for the treatment of autoimmune diseases. It is developed by Bristol-Myers Squibb.
Mechanism of Action[edit]
Lulizumab pegol works by targeting and inhibiting the PD-1 receptor, a protein that plays a major role in suppressing the immune system. By blocking this receptor, the drug enhances the body's immune response against disease-causing cells.
Clinical Trials[edit]
Lulizumab pegol has undergone clinical trials for the treatment of various autoimmune diseases, including lupus and rheumatoid arthritis. However, as of 2020, it has not yet been approved by the FDA or any other regulatory authority.
Side Effects[edit]
Like all drugs, lulizumab pegol can cause side effects. The most common ones reported in clinical trials include fatigue, nausea, and headaches. Severe side effects can include pneumonia and other serious infections due to the drug's effect on the immune system.
See Also[edit]
References[edit]
<references />
